There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Royalty Pharma (RPRX – Research Report) and Pro Medicus Limited (PMCUF – Research Report) with bullish sentiments.
Royalty Pharma (RPRX)
J.P. Morgan analyst Chris Schott maintained a Buy rating on Royalty Pharma yesterday and set a price target of $42.00. The company’s shares closed last Friday at $29.92.
According to TipRanks.com, Schott is a 3-star analyst with an average return of
Currently, the analyst consensus on Royalty Pharma is a Strong Buy with an average price target of $44.50, which is a 48.2% upside from current levels. In a report issued on February 5, Bank of America Securities also maintained a Buy rating on the stock with a $40.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Pro Medicus Limited (PMCUF)
In a report issued on February 15, David Low from J.P. Morgan maintained a Buy rating on Pro Medicus Limited, with a price target of A$104.00. The company’s shares closed last Friday at $58.67.
According to TipRanks.com, Low is a 2-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Pro Medicus Limited with a $60.40 average price target, a 2.9% upside from current levels. In a report issued on February 7, Jefferies also upgraded the stock to Buy with a A$120.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RPRX:
- TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels
- Royalty Pharma Reports Q4 and Full Year 2023 Results
- Royalty Pharma reports Q4 revenue $596M, consensus $691.65M
- Royalty Pharma Backs MorphoSys’s Acquisition with Strategic Investment
- Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
